Client News

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx to Report First Quarter 2026 Results on May 7, 2026

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis

Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic

CorTec’s Brain Interchange™ BCI System Enables Stroke Patient to Control Computer with his Mind

DINAMIQS receives Swissmedic license for viral vector manufacturing and testing

mbiomics Announces Third Closing of Series A, Reaching €30 Million to Advance Microbiome Therapeutics

Proxygen Expands Platform Beyond Degradation to Build Next-Generation Induced Proximity Therapeutics

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

AFYREN receives €3 million grant from the Grand Est Region through the European Just Transition Fund